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Abstract. Ventilation/perfusion lung scintigraphy was performed in 39 patients with verified diagnosis of community-
acquired pneumonia (CAP) and in 14 patients with peripheral lung cancer. Ventilation/perfusion ratio, apical-basal 
gradients of ventilation (U/L(V)) and lung perfusion (U/L(P)), and alveolar capillary permeability of radionuclide aerosol 
were determined based on scintigraphy data. The study demonstrated that main signs of CAP were increases in 
ventilation/perfusion ratio, perfusion and ventilation gradient on a side of the diseased lung, and two-side increase in 
alveolar capillary permeability rate for radionuclide aerosol. Unlike this, scintigraphic signs of peripheral lung cancer 
comprise an increase in ventilation/perfusion ratio over 1.0 on a side of the diseased lung with its simultaneous decrease 
on a contralateral side, normal values of perfusion and ventilation gradients of both lungs, and delayed alveolar capillary 
clearance in the diseased lung compared with the intact lung. 
Keywords: ventilation-perfusion lung scintigraphy, alveolar capillary permeability, peripheral lung cancer, community-
acquired pneumonia 
INTRODUCTION
Morbidity rate of community-acquired pneumonia (CAP) in Russia ranges from 14‰ to 15‰ and annual 
number of sufferers exceeds 1.5 million people [1]. Modern diagnostics of this disease is a relevant problem of 
pulmonology [2]. Main cause of challenges consists in similarity of clinical presentation of CAP and other diseases 
manifesting with development of infiltrative processes in the lungs (malignant neoplasms, infiltrative pulmonary 
tuberculosis, pulmonary embolism, etc.) [3–6]. The process for developing a differential diagnosis between CAP 
and peripheral lung cancer is associated with particular difficulties [3]. There is evidence that at least 15% of all 
oncological morbidity accounts for lung cancer. Moreover, the number of patients suffering from this disease 
increases by 3.5% annually and the efficacy of comprehensive treatment of pulmonary neoplasms directly depends 
on the timing of their detection [7]. 
Unfortunately, 60% to 90% of initial patients with lung cancer undergo wrongful treatment for pneumonia, 
tuberculosis, and some other diseases [4, 6]. The causes of late diagnosis of lung cancer generally comprise 
symptom non-specificity resulting in high likelihood of false negative results of chest X-ray examination [4]. 
As known, X-ray methods mainly characterize morphological changes in the lungs. Due to this, radionuclide 
methods of study are of special interest for clinicians because they allow for evaluating not only anatomical 
structures, but also functional features of the pathological process in respiratory organs [5, 8, 9]. 
Radionuclide pulmonary studies proved their diagnostic value in pulmonary embolism and in nonspecific acute 
and chronic lung diseases [2, 5, 10]. Noninvasiveness, relatively low radiation exposure, convenience for patients, 
and comparative simplicity of the procedure allow for administering this study even at an outpatient stage [11].  
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The weight of evidence suggests that ventilation/perfusion scintigraphy may be considered an essential approach 
for acquiring additional information in establishing the differential diagnosis at a stage of infiltrative changes in 
pulmonary parenchyma in CAP and in peripheral lung cancer [5, 8, 9]. 
The aim of this study was to elucidate new capabilities of ventilation/perfusion scintigraphy in differential 
diagnosis of CAP and peripheral lung cancer. 
MATERIALS AND METHODS 
The study comprised 53 men with pulmonary infiltrates. Patients suffering from CAP of different localizations 
were assigned to group 1 (mean age of 35.4 ± 6.8 years, n = 39). Patients with verified diagnosis of peripheral lung 
cancer were assigned to group 2 (mean age of 56.5 ± 3.2 years, n = 14). Patients of group 1 were non-smokers; 
patients of group 2 were smokers. Consistently, control group (n = 20) comprised healthy volunteers including 
10 non-smokers and 10 smokers of similar age and gender. This design of control group was based on the fact that 
smoking significantly affects alveolar capillary permeability (ACP), one of the most essential scintigraphic 
parameters of lung parenchyma [9]. 
All subjects underwent ventilation/perfusion lung scintigraphy examination. Scintigraphy studies were 
performed using emission computed tomography system with rotating dual head gamma-camera (Forte, Philips). 
Images were recorded to 128×128 matrix on specialized computer. Acquired scintigrams were processed using 
application software package SCINTI (NPO HELMOS, Russia). Initially, ventilation lung scintigraphy was 
performed; then, perfusion lung scintigraphy was conducted. All radionuclide studies were approved by the local 
ethics committee of the authors’ institute; informed consent was received from all patients. 
Technetium-99m (99mTc)-labeled macroaggregated human serum albumin was used as a radiopharmaceutical in 
perfusion lung scintigraphy. The studies were performed in four standard projections 5 min after the injection in 
sitting patients. Scintigram registration was done in static regime and lasted until accumulation of 300,000 counts 
per each position. Based on lung perfusion scintigraphy data, lung shape and sizes, radiopharmaceutical distribution 
homogeneity, presence of perfusion defects, and percentage of radiopharmaceutical accumulation by an individual 
lung were determined. 
Lung ventilation scintigraphy was performed immediately after aerosol inhalation using 99mTc-labeled 
diethylenetriamine pentaacetate (DTPA). To prepare radioactive aerosol, 3 mL of the radiopharmaceutical with 
specific activity of 74-111 MBq were placed in a nebulizer. Inhalation mixture was supplied under pressure of 0.5–
0.7 MPa. Scintigraphic images were registered in posterior frontal projection (POST) at 1 min after inhalation and, 
then, in anterior frontal (ANT) and lateral projections (LL 90°, RL 90°). At 10 and 30 min after finishing 
radiopharmaceutical inhalation, static lung scintigraphy was repeated only in posterior frontal. Exposure time was 
2 min for each projection. 
After completing the study, visual analysis of scintigraphic images was performed aimed at detection of 
ventilation defects in radiopharmaceutical accumulation. To calculate percentage of agent accumulation by each 
individual lung, mathematical analysis of ventilation scintigrams was performed. Alveolar capillary permeability 
was assessed by original technique developed by us [9, 10]. 
Acquired data were statistically processed by using STATISTICA 6.0 software for Windows. Quantitative 
parameters are presented as ? ± m. Most numerical variables were not normally distributed. Therefore, significance 
of differences for independent data sets was determined based on Mann–Whitney U test (or Wilcoxon test in case of 
dependent data sets). Values were considered statistically significant when P < 0.05. 
RESULTS AND DISCUSSION 
Results of the study showed that main parameters of lung ventilation/perfusion scintigraphy in healthy smokers 
and non-smokers were comparable and did not significantly differ between each other both for right and left lungs. 
Taking this into account, specified parameters were calculated for both lungs together. Depending on the fact of 
smoking, differences were observed only in ACP (Table 1). In smokers, this parameter was significantly higher both 
at 10 and 30 min of the study. This observation agrees with literature data. Similar changes in ACP were registered 
by G.L. Hungon et al. (1984) and Kanazava et al. (1993) [12–14] when they performed lung ventilation scintigraphy 
studies. Increase in the clearance rate of unhalted radiopharmaceutical can be explained by toxic effects of tobacco 
smoke on alveolar-capillary membrane. 
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TABLE 1. Parameters of ventilation/perfusion lung scintigraphy in healthy non-smokers and smokers (? ± m, ?) 
Parameters Healthy non-smokers* (n = 10) Healthy smokers* (n = 10) p
V/Q 0.98 ± 0.03 0.96 ± 0.03 0.7 
U/L(P) 0.68 ± 0.03 0.64 ± 0.05 0.17 
U/L(V) 0.66 ± 0.04 0.68 ± 0.08 0.49 
ACP, % (10 min) 10.6 ± 2.9 17.1 ± 3.8 0.03 
ACP, % (30 min) 21.3 ± 4.3 37.5 ± 5.2 0.004 
V/Q—ventilation perfusion ratio, U/L(P)—apical-basal ventilation gradient, U/L(P)—apical-basal perfusion gradient, 
ACP—alveolar capillary permeability, *—values are presented for both lungs together in control group, p—significance 
value for intergroup differences. 
 
In patients with CAP, ventilation/perfusion ratio (V/Q) was elevated in the diseased lung compared with that in 
the control group by about 8% (? = 0.01) (Table 2). In the healthy lung, V/Q did not exceed 1.0 (Table 2). Perfusion 
and ventilation gradients in the lung with infiltrate were significantly higher than corresponding values in control 
individuals (Table 2). The values of alveolar capillary permeability in both the diseased and intact lungs of CAP 
individuals significantly exceeded the control values. 
Increase in ventilation/perfusion ratio in the diseased lung of CAP patients suggested predominance of 
vasoconstrictor mechanism in the development of alveolar hypoxia. Significant increases in the apical-basal 
perfusion (U/L(P)) and ventilation (U/L(V)) gradients in the diseased lung as well as the accelerated ACP 
represented a compensatory reaction of alveolar capillary system in order to prevent the development of arterial 
hypoxemia in such patients [9, 10]. 
In patients of group 2 with peripheral lung cancer, V/Q ratio on a side of the diseased lung was significantly 
higher compared with the corresponding value in healthy smokers (Table 3). This observation suggests the 
predominance of microcirculatory disorders over ventilation disorders. At the contralateral side (reference intact 
lung), the V/Q ratio was decreased suggesting the compensatory vasodilation of pulmonary vessels. Alveolar 
capillary permeability in the diseased lung was attenuated compared with the corresponding value in control 
individuals (Table 3). Observed changes also represent one of the mechanisms preventing the development of 
arterial hypoxemia due to an increase in blood oxygenation time in the diseased lung. 
The results of a comparative analysis of scintigraphy studies in patients with CAP and peripheral lung cancer are 
presented in Table 4. As can be seen from Table 4, main differences were observed in the changes of ventilation-
perfusion matching and alveolar capillary permeability on a side of the diseased lung. For example, in patients with 
peripheral lung cancer, V/Q ratio was significantly higher on a side of the diseased lung compared with the 
corresponding value in CAP patients. Besides, apical-basal perfusion gradient (U/L(P)) was decreased and alveolar 
capillary permeability was attenuated suggesting more severe microcirculatory abnormalities in patients with lung 
cancer. 
TABLE 2. Parameters of ventilation/perfusion lung scintigraphy in patients with community-acquired pneumonia and  
in healthy non-smokers (? ± m, ?) 
Parameters for diseased and intact lungs CAP patients (n = 39) Healthy non-smokers* (n = 10) p
Diseased 1.06 ± 0.01 0.98 ± 0.03 0.04 
V/Q 
Intact 0.97 ± 0.03 0.98 ± 0.03 0.6 
Diseased 0.80 ± 0.02 0.68 ± 0.03 0.04 
U/L(P) 
Intact 0.69 ± 0.02 0.68 ± 0.03 0.93 
Diseased 0.77 ± 0.03 0.66 ± 0.04 0.05 
U/L(V) 
Intact 0.69 ± 0.02 0.66 ± 0.04 0.41 
Diseased 20.37 ± 1.41 10.6 ± 2.9 0.001 
ACP, % (10 min) 
Intact 18.11 ± 1.34 10.6 ± 2.9 0.006 
Diseased 35.86 ± 1.73 21.3 ± 4.3 0.001 
ACP, % (30 min) 
Intact 32.00 ± 1.71 21.3 ± 4.3 0.001 
V/Q—ventilation perfusion ratio, U/L(P)—apical-basal ventilation gradient, U/L(P)—apical-basal perfusion gradient, 
ACP—alveolar capillary permeability, CAP—community-acquired pneumonia, *—values are presented for both lungs 
together in control group, p—significance value for intergroup differences. 
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TABLE 3. Parameters of ventilation/perfusion lung scintigraphy in patients with peripheral lung cancer and  
in healthy non-smokers (? ± m, ?) 
Parameters for diseased and intact lungs PLC patients (n = 14) Healthy non-smokers* (n = 10) p
Diseased 1.13 ± 0.02 0.96 ± 0.03 0.001 
V/Q 
Intact 0.88 ± 0.02 0.96 ± 0.03 0.03 
Diseased 0.53 ± 0.08 0.64 ± 0.05 0.5 
U/L(P) 
Intact 0.57 ± 0.09 0.64 ± 0.05 0.35 
Diseased 0.84 ± 0.11 0.68 ± 0.08 0.054 
U/L(V) 
Intact 0.71 ± 0.05 0.68 ± 0.08 0.506 
Diseased 14.39 ± 2.84 17.1 ± 3.8 0.508 
ACP, % (10 min) 
Intact 14.00 ± 2.98 17.1 ± 3.8 0.691 
Diseased 24.54 ± 3.67 37.5 ± 5.2 0.006 
ACP, % (30 min) 
Intact 33.23 ± 3.14 37.5 ± 5.2 0.7 
V/Q—ventilation perfusion ratio, U/L(P)—apical-basal ventilation gradient, U/L(P)—apical-basal perfusion gradient, 
ACP—alveolar capillary permeability, PLC—peripheral lung cancer, *—values are presented for both lungs together in 
control group, p—significance value for intergroup differences. 
 
In summary, presented data suggest that the assessment of main parameters of lung ventilation/perfusion 
scintigraphy allows for extending the capabilities of differential diagnosis of CAP and peripheral ling cancer. 
CONCLUSION 
Main scintigraphic signs of CAP comprise increase in ventilation/perfusion ratio, perfusion gradient, and 
ventilation gradient on a side of the diseased lung compared with the corresponding values on the contralateral side 
as well as two-sided increase in ACP. 
Scintigraphic signs differentiating peripheral lung cancer from CAP are as follows: 
(i) Increase in ventilation/perfusion ratio over 1.0 on a side of the diseased lung. 
(ii) Decrease in V/Q ratio in the healthy lung. 
(iii) Normal values of ventilation gradient in both lungs and perfusion gradient of the intact lung. 
(iv) Attenuated alveolar capillary permeability in the diseased lung compared with the corresponding value in the 
intact lung. 
TABLE 4. Parameters of ventilation/perfusion lung scintigraphy in patients with community-acquired pneumonia and 
peripheral lung cancer (? ± m, ?) 
Parameters for diseased and intact lungs PLC patients (n = 14) CAP patients* (n = 39) p
Diseased 1.13±0.02 1.06±0.01 <0.001 
V/Q 
Intact 0.88±0.02 0.97±0.03 0.006 
Diseased 0.53±0.08 0.80±0.02 0.009 
U/L(P) 
Intact 0.57±0.09 0.69±0.02 0.168 
Diseased 0.84±0.11 0.77±0.03 0.955 
U/L(V) 
Intact 0.71±0.05 0.69±0.02 0.929 
Diseased 14.39±2.84 20.37±1.41 0.037 
ACP, % (10 min) 
Intact 14.00±2.98 18.11 ±1.34 0.161 
Diseased 24.54±3.67 35.86 ±1.73 0.06 
ACP, % (30 min) 
Intact 33.23±3.14 32.00 ±1.71 0.7 
V/Q—ventilation perfusion ratio, U/L(P)—apical-basal ventilation gradient, U/L(P)—apical-basal perfusion gradient, 
ACP—alveolar capillary permeability, CAP—community-acquired pneumonia, PLC—peripheral lung cancer, *—values are 
presented for both lungs together in control group, p—significance value for intergroup differences. 
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